MCL Literature Feed

A case report demonstrates that MCL can relapse in rare sites like skeletal muscle after rituximab maintenance, underscoring the value of PET/CT for detecting atypical disease progression.

A case of CD5+ cutaneous DLBCL highlights a diagnostic pitfall, as it can mimic MCL but is distinguished by cyclin D1 negativity, reinforcing the need for complete immunohistochemical workup.

This case of MCL presenting as diffuse gastrointestinal polyposis mimicking hereditary syndromes underscores the need for histopathology to avoid misdiagnosis and ensure prompt immunochemotherapy for this rare presentation.

This large retrospective study shows rituximab maintenance after first-line bendamustine-rituximab significantly improves both event-free and overall survival, supporting its use as a standard of care.

Population-level data confirms rituximab maintenance improves overall survival after R-CHOP induction, with a notable benefit for patients achieving only a partial response.

Co-expression of PD-L1/PD-1 with CXCR3 and systemic inflammation indices (SIRI, SII) identified advanced stage and poor survival in a mixed lymphoma cohort, offering potential prognostic biomarkers for MCL.

Emapalumab, an interferon-gamma blocker, successfully treated severe immune effector cell-associated HLH-like syndrome (IEC-HS) in a relapsed MCL patient post-CAR-T, offering a targeted approach for this life-threatening toxicity.

Prophylactic siltuximab, guided by rising CRP, effectively managed cytokine release syndrome from bispecifics while minimizing infections by avoiding corticosteroids, a promising toxicity management strategy for MCL patients.

This review summarizes the rapid clinical integration of T-cell engaging therapies (CAR-T, bispecifics) for B-NHL, including MCL, and outlines future strategies like earlier use and novel constructs.

This first reported case of mantle cell lymphoma with hypereosinophilia demonstrates a rare paraneoplastic presentation where eosinophil counts normalized following successful immunochemotherapy, expanding the disease's clinical spectrum.

This case report identifies chronic enteroviral meningoencephalitis as a severe neurotoxicity of rituximab maintenance in MCL, demonstrating successful resolution with intravenous immunoglobulins (IVIg) and fluoxetine.

A new immunocompetent mouse model co-expressing SOX11 and CCND1 faithfully recapitulates human MCL, providing a crucial platform for studying disease biology and testing novel immunotherapies.

Acalabrutinib plus rituximab successfully resolved paraneoplastic glomerulonephritis in an MCL patient, offering a new treatment approach for this rare renal complication.

This is the first study from North India providing real-world evidence that rituximab maintenance improves overall and event-free survival in MCL, validating this standard of care in an underrepresented population.

Pre-clinical CD20 CAR-T cells armed with H. pylori protein (NAP) kill rituximab-relapsed MCL cells and induce a bystander immune effect, potentially overcoming antigen-loss resistance.

Real-world data on the ibrutinib, lenalidomide, and rituximab triplet in relapsed/refractory non-Hodgkin lymphoma provides practical insights into the efficacy and safety of this chemotherapy-free regimen.

This case report of sequential follicular lymphoma, MCL, and CML highlights the long-term risk of subsequent malignancies and severe infections (COVID-19-induced HLH) following repeated immunochemotherapy.

New prognostic scores, AMOS and AMES, were developed for Indian MCL patients, showing better predictive accuracy than MIPI using simple clinical factors for improved risk stratification.

This phase 1 study shows the novel chemo-free triplet of magrolimab (anti-CD47), obinutuzumab, and venetoclax is a potential strategy for relapsed/refractory B-cell lymphomas, including MCL.

This review summarizes favorable outcomes for CAR-T and bispecific antibodies in relapsed/refractory MCL, detailing their integration into the treatment paradigm for patients with poor prognoses post-BTKi.

The chemotherapy-free triplet of acalabrutinib (BTKi), umbralisib (PI3Ki), and ublituximab (anti-CD20) achieved high response and MRD-negativity rates in untreated MCL, presenting a novel frontline option.

This large pooled analysis of 1280 trial patients validates progression within 24 months (POD24) as a robust indicator of poor survival, with rituximab maintenance reducing this risk.

The CD20xCD3 bispecific antibody glofitamab induces high and durable complete response rates in heavily pretreated relapsed/refractory MCL, providing a new off-the-shelf immunotherapy option post-BTKi failure.

This correspondence provides expert commentary and clarification on the pivotal trial data for the bispecific antibody glofitamab in patients with relapsed/refractory mantle cell lymphoma.

This case report describes a rare paraneoplastic syndrome in MCL causing severe thrombocytopenia via both bone marrow failure and immune destruction, which responded to lymphoma-directed chemoimmunotherapy but not standard ITP treatment.

Genomic analysis of a single MCL patient identified specific mechanisms of resistance to PD-L1 blockade, providing crucial insights into why checkpoint inhibitors are often ineffective in this lymphoma.

This review summarizes the expanding role of T-cell directing immunotherapies, like bispecifics and CAR-T, in treating relapsed/refractory NHL, providing a framework for their application in MCL.

In previously untreated, transplant-ineligible MCL, achieving MRD-negativity after bendamustine-obinutuzumab induction allows for the safe omission of maintenance therapy without worsening progression-free survival.

Long-term follow-up of the Philemon trial confirms durable responses for the chemotherapy-free triplet of ibrutinib, lenalidomide, and rituximab in relapsed/refractory MCL.

Preclinical data shows the TKI anlotinib inhibits MCL proliferation by targeting the PI3K/AKT/mTOR pathway and modulates the tumor microenvironment, identifying a potential new oral therapy for MCL.